Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · IEX Real-Time Price · USD
7.53
-0.41 (-5.16%)
Apr 25, 2024, 9:40 AM EDT - Market open
Recursion Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RXRX stock have an average target of 17.4, with a low estimate of 10 and a high estimate of 33. The average target predicts an increase of 131.08% from the current stock price of 7.53.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RXRX stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $17 | Strong Buy | Reiterates | $17 | +125.76% | Apr 9, 2024 |
| Keybanc | Keybanc | Buy Maintains $15 → $16 | Buy | Maintains | $15 → $16 | +112.48% | Mar 4, 2024 |
| Needham | Needham | Strong Buy Maintains $15 → $17 | Strong Buy | Maintains | $15 → $17 | +125.76% | Feb 28, 2024 |
| TD Cowen | TD Cowen | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jan 26, 2024 |
| Needham | Needham | Strong Buy Reiterates $15 | Strong Buy | Reiterates | $15 | +99.20% | Jan 17, 2024 |
Financial Forecast
Revenue This Year
57.28M
from 44.58M
Increased by 28.50%
Revenue Next Year
90.20M
from 57.28M
Increased by 57.47%
EPS This Year
-1.76
from -1.58
EPS Next Year
-1.90
from -1.76
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 87.5M | 267.7M | 218.4M |
| Avg | 57.3M | 90.2M | 154.3M |
| Low | 42.1M | 41.1M | 92.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | 96.2% | 367.3% | 142.1% |
| Avg | 28.5% | 57.5% | 71.0% |
| Low | -5.5% | -28.3% | 2.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | -1.56 | -1.18 | -1.29 |
| Avg | -1.76 | -1.90 | -1.53 |
| Low | -2.06 | -3.43 | -1.89 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.